NCT07552194Not yet recruiting
Stenting Versus Drug Eluting Balloons Only in Treatment of Coronary Bifurcation Lesion (ROBUST Study)
CompaRison of corOnary BifUrcation Treatment With and Without Stenting Using Only Drug eluTing Balloons (ROBUST Study)
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn immediate and follow up results of percutaneous treatment of coronary bifurcation lesion using drug eluting balloons (DEB) only in patients with chronic coronary syndrome (CCS). Researchers will compare endovascular treatment using solely DEB to stenting of coronary bifurcation lesion. The main questions it aims to answer are: * What is immediate and follow up clinical and angiographic results of endovascular treatment of coronary bifurcation lesion using DEB in patients with CCS? * Is efficacy and safety of endovascular treatment of coronary bifurcation lesion using DEB only in patients with CCS non inferior to compare stenting of aforementioned lesion which is contemporary recommended standard of care? Participants will: * Take prescribed medication before and after initial procedure during whole observation period (12 months) * Visit the clinic at 1, 6 and 12 months after the initial procedure for checkup, noninvasive tests and control angiography at 12 months follow up * Inform researchers about all adverse events that might be occur during follow up observation period
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 272 (estimated)
- First submitted
- 4 Mar 2026
- Start date
- Jun 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- Avtandil M. Babunashvili
- Diseases
- Coronary artery disease
- NCT number
- NCT07552194
What you commit to
- Study type: Interventional
- Planned participants: 272
- From Jun 2026 to the primary completion date, Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant cancer
- In-stent restenosis in bifurcation lesions after previously performed PCI
- Without concomitant chronic occlusion (bifurcation included in the chronic coronary occlusion (CTO))
- Patient non-adherence to therapy, including antiplatelet and/or anticoagulant medications
Other illness
- Severe valvular heart disease requiring surgical or percutaneous intervention within 1 year
- Chronic renal failure (glomerular filtration rate less than 30 ml/min)
- Heart failure \> NYHA class II
- Patients at high bleeding risk (according to the PRECISE-DAPT score)
- Episodes of significant bleeding and ongoing bleeding requiring modification of medical therapy
- Acute coronary syndrome
Lab values
- LV ejection fraction according to echocardiography ≤ 0.4
- Anemia (Hb \< 10 g/dL)
Age
- Over 80 years of age
Other
- Patients with a single remaining artery supplying a large area of myocardium at risk, regardless of its caliber
- Bifurcation stenosis of the left main coronary artery and bifurcation lesions other than 1.1.1; 1.0.1, and 0.1.1 according to the Medina classification
- The difference between the proximal and distal reference diameter of the main artery is \> 1 mm
- Pregnancy or breastfeeding
- Life expectancy less than 1 year.
- Presence of thrombus containing Lesion
- Thrombocytopenia and any coagulopathy
- PCI or coronary artery bypass grafting (CABG) performed according to clinical indications
Who the study is looking for
- Patients with CCS with documented myocardial ischemia in area supplying by the target coronary artery, not older than 80 years and with an expected life expectancy of at least 1 year
- Patients with single- or multivessel disease and "true" (1.1.1; 1.1.0; and 0.1.1 according to the Medina classification) de novo bifurcation stenosis \> 50% and \<100% of the main coronary artery (excluding of the left main) or their large side branches.
- Both main and side branches should be ≥ 2.0 mm and ≤ 4.5 mm in diameter (according to Quantitative coronary angiography - QCA or intravascular imaging)
- Length of the main branch lesion should be no more than 30 mm
- The total length of the side branch should be no more than 7 cm, and the side branch lesion length should be no more than 10 mm
- Patients without hereditary coagulopathies
- With a recent (at least 3 months) history of acute coronary syndrome (ACS)
- Signed informed consent by patient to participate in the study
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.